(Q44784933)

6 December 2017

title

Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation (English)

1 reference

ORCID Public Data File 2021

6 December 2017

1 reference

1 reference

author name string

Talitha I Verhoef

1

1 reference

6 December 2017

William K Redekop

2

1 reference

6 December 2017

David L Veenstra

3

1 reference

6 December 2017

Rahber Thariani

4

1 reference

6 December 2017

Peter A Beltman

5

1 reference

6 December 2017

Rianne Mf van Schie

6

1 reference

6 December 2017

Anthonius de Boer

7

1 reference

6 December 2017

Anke-Hilse Maitland-van der Zee

8

1 reference

6 December 2017

EU-PACT Group

9

1 reference

6 December 2017

publication date

1 June 2013

1 reference

6 December 2017

1 reference

6 December 2017

volume

14

1 reference

6 December 2017

issue

8

1 reference

6 December 2017

page(s)

869-883

1 reference

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

6 December 2017

cites work

1 reference

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

Pharmacogenetics of oral anticoagulant therapy

21 January 2018

1 reference

The Scylla and Charybdis of oral anticoagulant treatment.

21 January 2018

1 reference

Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio?

21 January 2018

1 reference

Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action

21 January 2018

1 reference

Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients

21 January 2018

1 reference

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data

21 January 2018

1 reference

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

21 January 2018

1 reference

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

21 January 2018

1 reference

A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).

21 January 2018

1 reference

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design

21 January 2018

1 reference

Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial

21 January 2018

1 reference

Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design

21 January 2018

1 reference

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing

21 January 2018

1 reference

Death and disability from warfarin-associated intracranial and extracranial hemorrhages

21 January 2018

1 reference

Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis

21 January 2018

1 reference

Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes

21 January 2018

1 reference

Future costs of stroke in the Netherlands: the impact of stroke services

21 January 2018

1 reference

Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs

21 January 2018

1 reference

A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives

21 January 2018

1 reference

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation

21 January 2018

1 reference

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.

21 January 2018

1 reference

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation

21 January 2018

1 reference

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

21 January 2018

1 reference

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.13.74

1 reference

6 December 2017

1 reference